Lomustine
Disability Evaluation
European Organisation for Research and Treatment of Cancer - EORTCSmall moleculePhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Disability Evaluation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 | BB |
(+)-VINCRISTINE European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 | B |
Same molecule, other indications
Lomustine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →